KR910004591A - 헤테로 고리 화합물 - Google Patents

헤테로 고리 화합물 Download PDF

Info

Publication number
KR910004591A
KR910004591A KR1019900011964A KR900011964A KR910004591A KR 910004591 A KR910004591 A KR 910004591A KR 1019900011964 A KR1019900011964 A KR 1019900011964A KR 900011964 A KR900011964 A KR 900011964A KR 910004591 A KR910004591 A KR 910004591A
Authority
KR
South Korea
Prior art keywords
lower alkyl
hydrogen
phenyl
substituted
nitrogen
Prior art date
Application number
KR1019900011964A
Other languages
English (en)
Inventor
히로시 하라다
에이이찌 오오스기
유끼오 요네따니
도시히로 시노사끼
Original Assignee
요시또시 가즈오
시노오 기세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요시또시 가즈오, 시노오 기세이야꾸 가부시끼가이샤 filed Critical 요시또시 가즈오
Publication of KR910004591A publication Critical patent/KR910004591A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Abstract

내용 없음.

Description

헤테로 고리 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. 하기식(I)의 화합물.
    (식에서 R1과 R2는 독립적으로 수소, 저급알킬, 페닐 또는 치환페닐이거나, 또는 R1과 R2는 그들이 결합된 탄소원자와 함께 4-원∼S-원 탄소고리를 형성할수 있으며; R3은 수소 또는 저급알킬이며; R4는 수소, 할로겐, 니트로, 저급알킬, 페닐, 치환페닐, -OR5및 -SO2NR6R6′로 구성되는 군에서 선택되는 1 또는 2 라디칼이며; R5는 수소, 저급알킬, 페닐-치환 저급알킬, 카르복시메틸 또는 그의 에스테르, 히드록시에틸 또는 그의 에테르, 또는 알릴이며; R6와 R6′는 독립적으로 수소 또는 저급알킬이며 ; R7은 수소 또는 약학적 활성 에스테르 형성기이며; A는 1∼-5탄소원자를 갖는 직쇄 또는 분지쇄 탄화수소라디칼이며; B는 할로겐, 산소, 또는 디리올란이며; Y는 산소, 황, 질소 또는 치환질소이며; Z는 산소, 질소 또는 치환질소이며; 점선은 단일 결합의 존재 또는 부재를 나타낸다.)
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900011964A 1989-08-03 1990-08-03 헤테로 고리 화합물 KR910004591A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1203024A JPH0366669A (ja) 1989-08-03 1989-08-03 複素環式化合物
JP203024/89 1989-08-03

Publications (1)

Publication Number Publication Date
KR910004591A true KR910004591A (ko) 1991-03-29

Family

ID=16467086

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900011964A KR910004591A (ko) 1989-08-03 1990-08-03 헤테로 고리 화합물

Country Status (5)

Country Link
US (1) US5268386A (ko)
EP (1) EP0415566A1 (ko)
JP (1) JPH0366669A (ko)
KR (1) KR910004591A (ko)
CA (1) CA2021926A1 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374643A (en) * 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
US6790965B1 (en) * 1994-05-06 2004-09-14 Pharmacopeia Drug Discovery, Inc. Combinatorial dihydrobenzopyran library
US5612370A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phenylglycine and phenylalaninen amido benzopyran derivatives
US5629429A (en) * 1995-06-07 1997-05-13 Bristol-Myers Squibb Company Process for preparing 4-arylamino-benzopyran and related compounds
US5612323A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phosphinic ester substituted benzopyran derivatives
US5869478A (en) * 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
CA2413201A1 (en) 2000-06-28 2002-01-03 Merck & Co., Inc. Treatment for cardiovascular disease
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
BRPI0519013A2 (pt) * 2004-12-13 2009-11-03 Lilly Co Eli composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto
US8841333B2 (en) * 2005-05-09 2014-09-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating nephrolithiasis
WO2007019153A2 (en) * 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
EP2101761A4 (en) * 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
EP2613780B1 (en) 2010-09-10 2014-11-12 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
CN111803499B (zh) * 2018-06-13 2021-09-14 四川轻化工大学 一种治疗抗痛风、抗高尿酸血症的药物组合物ⅱ
KR20210042104A (ko) * 2018-08-10 2021-04-16 산토리 홀딩스 가부시키가이샤 요산 배출 촉진용 조성물, urat1 저해용 조성물 및 혈중 요산치 저하용 조성물
CN112661738B (zh) * 2020-12-31 2023-01-10 南方医科大学 二氢黄酮类化合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518015C3 (de) * 1965-04-23 1974-06-06 Merck Patent Gmbh, 6100 Darmstadt Substituierte Flavanderivate sowie Verfahren zu ihrer Herstellung
FR2148363A1 (en) * 1971-08-11 1973-03-23 Ferlux Dihydrobenzopyran derivs - as cardiac and respiratory analeptic agents and hypo tensive agents
DE2535338A1 (de) * 1975-08-07 1977-02-17 Bayer Ag Chromanone-(4)
CH619701A5 (ko) * 1975-08-07 1980-10-15 Bayer Ag
ZA844519B (en) * 1983-06-24 1985-02-27 Hoffmann La Roche Dihydrobenzopyran derivatives
ZA873745B (en) * 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives

Also Published As

Publication number Publication date
CA2021926A1 (en) 1991-02-04
US5268386A (en) 1993-12-07
EP0415566A1 (en) 1991-03-06
JPH0366669A (ja) 1991-03-22

Similar Documents

Publication Publication Date Title
KR910004591A (ko) 헤테로 고리 화합물
MX9307052A (es) Derivados del taxano sustituidos con furil-carbonilo o tienil-carbonilo y composiciones farmaceuticas que los contienen.
KR910016742A (ko) 알킬화된 옥소-피페라진일-트리아진
LU91196I2 (fr) Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO).
KR890000489A (ko) 6 환 화합물
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
KR920003968A (ko) 염증성 장 질환의 치료방법
KR950703503A (ko) 4-알콕시-2,6-디-t-부틸페놀 유도체(4-ALKOXY-2,6-DI-t-BUTYLPHENOL DERIVATVE)
KR920009399A (ko) 면역 억제 활성을 갖는 약제를 제조하기 위한 크산틴의 용도
RU95106653A (ru) Производные 2-имидазолин-5-онов и 2-имидазолин-5-тионов и фунгицидные композиции на их основе
KR910014119A (ko) 항-고혈압 활성을 갖는 티아졸리딘 유도체 및 그의 치료용도
KR920016089A (ko) 제i형 당뇨병의 치료방법
KR970707122A (ko) 퀴놀린 유도체(quinoline derivative)
KR880012590A (ko) 신규 함질소 화합물
KR890014448A (ko) 아실페놀 유도체
ES458557A1 (es) Un procedimiento de preparacion de derivados de quinazolina.
FR3071850B1 (fr) Composition d’additifs pour carburant
MX9301345A (es) Procedimineto para la preparacion de derivados de taxano.
KR920009397A (ko) 사람 레트로바이러스의 복제를 억제하는데 효과적인 약제를 제조하기 위한 크산틴의 용도
KR920014818A (ko) 항균제
KR900006285A (ko) 소염성 3-아실-2-옥신돌-1-카복사미드의 전구약제
ATE7025T1 (de) 4-carbamoylimidazol-5-ol-derivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
KR900004706A (ko) Lo/co 억제 벤즈옥사졸론
AR018985A1 (es) Uso de una composicion farmaceutica para prevenir infecciones por vih y otras infecciones retrovirales
KR890008121A (ko) 로다닌 유도체 및 약제학적 조성물

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid